<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00410358</url>
  </required_header>
  <id_info>
    <org_study_id>CLBQ707A1101</org_study_id>
    <nct_id>NCT00410358</nct_id>
  </id_info>
  <brief_title>A Dose Escalation of Gimatecan Administered Orally to Japanese Patients With Advanced Solid Tumor.</brief_title>
  <official_title>A Phase I Dose Escalation Study of LBQ707 (Gimatecan) Administered Orally 5 Consecutive Days to Japanese Patients With Advanced Solid Tumor.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study assesses the tolerability, safety, efficacy and pharmacokinetics of gimatecan in&#xD;
      Japanese patients. Gimatecan is administered orally for five consecutive days, every 28 days,&#xD;
      to adult patients with advanced solid tumors who have progressed despite standard therapy or&#xD;
      for whom standard systemic therapy does not exist.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimated Maximum Tolerated Dose of gimatecan</measure>
    <time_frame>1.8 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by adverse events</measure>
    <time_frame>1.8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of the pharmacokinetic profile of gimatecan</measure>
    <time_frame>1.8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity assessed by RECIST</measure>
    <time_frame>1.8 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>LBQ707</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gimatecan</intervention_name>
    <arm_group_label>LBQ707</arm_group_label>
    <other_name>LBQ707</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with histological or cytological confirmed advanced solid tumors, which have&#xD;
             progressed despite standard therapy or for whom no standard therapy exists.&#xD;
&#xD;
          -  Life expectancy of at least 3 months&#xD;
&#xD;
          -  Adequate hematological parameters&#xD;
&#xD;
          -  No major impairment of renal and hepatic function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Gastrointestinal dysfunction, such as gastrectomy and malabsorption syndrome that&#xD;
             could alter absorption.&#xD;
&#xD;
          -  Patients who have received any investigational compound within the past 28 days.&#xD;
&#xD;
          -  Patients with other antineoplastic therapy within the last 28 days.&#xD;
&#xD;
          -  Patients known to be HIV or hepatitis virus positive, or patients with the presence of&#xD;
             active or suspected acute or chronic uncontrolled infection&#xD;
&#xD;
          -  Patients with a history of allergies to the camptothecin family drug.&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chiba Prefecture</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=3945</url>
    <description>Results for CLBQ707A1101 can be found on the Novartis Clinical Trial Results Website</description>
  </link>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>December 11, 2006</study_first_submitted>
  <study_first_submitted_qc>December 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2006</study_first_posted>
  <last_update_submitted>December 16, 2020</last_update_submitted>
  <last_update_submitted_qc>December 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gimatecan</keyword>
  <keyword>topoisomerase I inhibitor</keyword>
  <keyword>advanced solid tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

